In addition to the drug resistance conferred by the C797S mutation in EGFR, amplification of the MET gene as a bypass pathway, alteration in RAS-RAF-MAPK pathway, ROS1 fusion gene, PIK3CA mutation, and transformation to small cell lung cancer are other mechanisms that impart drug resistance. This evidence concerns the gene EGFR and small cell lung carcinoma.